Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.66 |
| ▸ | CBR1 | P16152 | 1/20 | 0.66 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.66 |
| ▸ | ACLY | P53396 | 1/20 | 0.66 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | F13A1 | P00488 | 1/20 | 0.49 |
| ▸ | TGM2 | P21980 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pochonin A SCHEMBL10150818 | 1.00 | HSP90AB1 (1.00) | HSP90AB1MAPTHSP90AA1GAARAB9A | |
| Pochonin A SCHEMBL10150715 | 1.00 | HSP90AB1 (1.00) | HSP90AB1MAPTHSP90AA1GAARAB9A | |
| Pochonin A SCHEMBL10150098 | 1.00 | HSP90AB1 (1.00) | HSP90AB1MAPTHSP90AA1GAARAB9A | |
| Pochonin A SCHEMBL10150114 | 1.00 | HSP90AB1 (1.00) | HSP90AB1MAPTHSP90AA1GAARAB9A | |
| Pochonin A SCHEMBL10150819 | 1.00 | HSP90AB1 (1.00) | HSP90AB1MAPTHSP90AA1GAARAB9A | |
| Pochonin A SCHEMBL10150463 | 1.00 | HSP90AB1 (1.00) | HSP90AB1MAPTHSP90AA1GAARAB9A | |
| Pochonin A SCHEMBL19418057 | 1.00 | HSP90AB1 (1.00) | HSP90AB1MAPTHSP90AA1GAARAB9A | |
| SCHEMBL10150470 | 0.89 | HSP90AB1 (0.80) | HSP90AB1MAPTHSP90AA1GAARAB9A | |
| SCHEMBL19418343 | 0.88 | HSP90AB1 (0.78) | HSP90AB1MAPTHSP90AA1GAARAB9A | |
| SCHEMBL10150100 | 0.87 | HSP90AB1 (0.77) | HSP90AB1MAPTHSP90AA1GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239856-B2 | Synthesis of resorcylic acid lactones useful as therapeutic agents | UNIVERSITY DE STRASBOURG (FR) | 2019-03-26 | — | — | US | disclosed |
| EP-2136799-B1 | MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 | UNIV STRASBOURG (FR) | 2017-10-04 | — | — | EP | disclosed |
| EP-2254880-B1 | Macrocyclic prodrug compounds useful as therapeutics | NEXGENIX PHARMACEUTICALS (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-2242359-B1 | SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS | UNIV STRASBOURG (FR) | 2016-06-01 | — | — | EP | disclosed |
| US-20160075677-A1 | SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS | UNIVERSITE DE STRASBOURG (FR) | 2016-03-17 | — | — | US | disclosed |
| US-9051302-B2 | Synthesis of resorcylic acid lactones useful as therapeutic agents | UNIVERSITE DE STRASBOURG (FR) | 2015-06-09 | — | — | US | disclosed |
| CN-102015673-B | Macrocyclic prodrug compounds for use as therapeutic agents | ONCOSYNERGY INC. (US) | 2014-10-29 | — | — | CN | disclosed |
| US-20140135290-A1 | MACROCYCLIC PRODRUG COMPOUNDS USEFUL AS THERAPEUTICS | ONCOSYNERGY, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| CN-103539769-A | Macrocyclic compounds useful as inhibitors of kinases and HSP90 | UNIV STRASBOURG | 2014-01-29 | — | — | CN | disclosed |
| CN-101588799-B | Macrocyclic compounds useful as kinase inhibitors and HSP90 inhibitors | UNIV STRASBOURG | 2013-09-11 | — | — | CN | disclosed |
| EP-2254880-A2 | MACROCYCLIC PRODRUG COMPOUNDS USEFUL AS THERAPEUTICS | Nexgenix Pharmaceuticals (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20100292218-A1 | Treatment Of Neurofibromatosis With Radicicol And Its Derivatives | NEXGENIX PHARMACEUTICALS HOLDINGS, INC. | 2010-11-18 | — | — | US | disclosed |
| EP-2242359-A1 | SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS | Universite De Strasbourg (FR) | 2010-10-27 | — | — | EP | disclosed |
| EP-2136799-A1 | MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 | Universite De Strasbourg (FR) | 2009-12-30 | — | — | EP | disclosed |
| CN-101588799-A | Macrocyclic compounds useful as kinase inhibitors and HSP90 inhibitors | UNIV STRASBOURG (FR) | 2009-11-25 | — | — | CN | disclosed |
| WO-2009105755-A2 | MACROCYCLIC PRODRUG COMPOUNDS USEFUL AS THERAPEUTICS | NEXGENIX PHARMACEUTICALS (US) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009091921-A1 | SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS | UNIVERSITE DE STRASBOURG (FR) | 2009-07-23 | — | — | WO | disclosed |
| WO-2008150302-A1 | TREATMENT OF NEUROFIBROMATOSIS WITH RADICICOL AND ITS DERIVATIVES | NEXGENIX PHARMACEUTICALS (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080146545-A1 | Macrocyclic compounds useful as inhibitors of kinases and HSP90 | UNIVERSITE DE STRASBOURG (FR) | 2008-06-19 | — | — | US | disclosed |
| WO-2008021213-A1 | MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 | WINSSINGER NICOLAS (FR) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292218-A1 | Treatment Of Neurofibromatosis With Radicicol And Its Derivatives | HSP90AB2P, HSP90AA1, HSPA2 | HSP90AB1 4/4885MAPT 2339/4885HSP90AA1 2/4885 |
| US-10239856-B2 | Synthesis of resorcylic acid lactones useful as therapeutic agents | HSP90AA1, HSP90AB1, HSP90AB2P | HSP90AB1 2/4885MAPT 1374/4885HSP90AA1 1/4885 |
| US-20080146545-A1 | Macrocyclic compounds useful as inhibitors of kinases and HSP90 | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AB1 1/4885MAPT 1982/4885HSP90AA1 2/4885 |
| US-20140135290-A1 | MACROCYCLIC PRODRUG COMPOUNDS USEFUL AS THERAPEUTICS | ADCYAP1R1, CYP19A1, THOP1 | HSP90AB1 3953/4885MAPT 2173/4885HSP90AA1 4055/4885 |
| US-20160075677-A1 | SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS | HSP90AA1, HSP90AB1, HSP90AB2P | HSP90AB1 2/4885MAPT 1374/4885HSP90AA1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.